Radioligand therapy is an emerging technology in which radiation is selectively targeted to tumors using molecular targeting, enabling effective tumor treatment with minimal toxicity in many cases. When paired with high-quality PET imaging agents utilizing the same targeting agent, this method allows physicians to “see what they treat,” using the theranostic strategy.
In particular, targeted alpha therapy (TAT) using radioimmunotherapy may be employed to deliver very high doses of highly lethal alpha particles to tumors. In this method, highly specific targeting immunoglobulins labeled with alpha emitters such as 225Ac are administered, which are highly effective for tumor control.
“At UCSF Radiology, we have developed a highly effective TAT agent, 225Ac-DOTA-YS5, for the treatment of prostate cancer, and verified its activity in prostate cancer models,” says Kondapa Naidu…
